Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Alafenamide Fumarate

恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦

Report date: 2026/03/18 10:10:47

Base Information

Drug NameEmtricitabine/Rilpivirine Hydrochloride/Tenofovir Alafenamide Fumarate
Drug Alias Name盐酸利匹韦林/富马酸磷丙替诺福韦/恩曲他滨FTC/RPV/TAF恩曲他滨/富马酸磷丙替诺福韦/盐酸利匹韦林Emtricitabine/Tenofovir Alafenamide Fumarate/Rilpivirine HydrochlorideRilpivirine Hydrochloride/Tenofovir Alafenamide Fumarate/Emtricitabine +[12] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2016/03/01
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsYes EmtricitabineTenofovir Alafenamide FumarateRilpivirine Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead IncJohnson & Johnson Innovative MedicineJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineGilead Sciences IncGilead Sciences Ireland Uc
Inactive CompaniesQilu Pharmaceutical Co Ltd
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR19
Related LinksKEGG